Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.48

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.04

EPS Last/This Y

0.53

EPS This/Next Y

0.08

Price

1.14

Target Price

4.95

Analyst Recom

2.25

Performance Q

-4.17

Relative Volume

1.09

Beta

2.22

Ticker: FATE




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25FATE1.2350.070.626450
2025-07-28FATE1.3050.080.006545
2025-07-29FATE1.160.080.296629
2025-07-30FATE1.1350.080.006632
2025-07-31FATE1.10.080.006739
2025-08-01FATE1.0650.080.006731
2025-08-04FATE1.060.080.136735
2025-08-05FATE1.080.080.006725
2025-08-06FATE1.0450.080.006725
2025-08-07FATE0.980.080.126725
2025-08-08FATE0.92070.090.006272
2025-08-11FATE0.93750.09999.996497
2025-08-12FATE0.9440.090.006507
2025-08-13FATE1.150.080.416464
2025-08-14FATE1.080.090.006628
2025-08-15FATE1.080.100.006217
2025-08-18FATE1.190.141.132825
2025-08-19FATE1.140.170.002979
2025-08-20FATE1.1250.160.003240
2025-08-21FATE1.120.160.863254
2025-08-22FATE1.1450.170.073317
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25FATE1.24-1.4- -1.24
2025-07-28FATE1.30-1.4- -1.24
2025-07-29FATE1.17-1.4- -1.24
2025-07-30FATE1.14-1.4- -1.24
2025-07-31FATE1.10-1.4- -1.24
2025-08-01FATE1.07-4.3- -1.29
2025-08-04FATE1.06-4.3- -1.29
2025-08-05FATE1.08-4.3- -1.29
2025-08-06FATE1.05-4.3- -1.29
2025-08-07FATE0.98-4.3- -1.29
2025-08-08FATE0.92-4.3- -1.29
2025-08-11FATE0.94-4.3- -1.29
2025-08-12FATE0.94-4.3- -1.29
2025-08-13FATE1.13-4.3- -1.29
2025-08-14FATE1.08-4.3- -1.29
2025-08-15FATE1.09-4.3- -1.12
2025-08-18FATE1.1830.7- -1.12
2025-08-19FATE1.1430.7- -1.12
2025-08-20FATE1.1230.7- -1.12
2025-08-21FATE1.1230.7- -1.12
2025-08-22FATE1.1431.2- -1.11
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25FATE0.00-6.368.83
2025-07-28FATE0.00-6.038.83
2025-07-29FATE0.00-6.038.83
2025-07-30FATE0.00-6.038.83
2025-07-31FATE0.00-6.038.83
2025-08-01FATE0.00-6.038.83
2025-08-04FATE0.00-7.838.83
2025-08-05FATE-0.31-7.838.83
2025-08-06FATE-0.31-7.838.83
2025-08-07FATE-0.31-7.838.83
2025-08-08FATE-0.31-7.838.83
2025-08-11FATE-0.31-7.848.83
2025-08-12FATE-0.31-7.848.66
2025-08-13FATE-0.31-7.848.66
2025-08-14FATE-0.31-7.848.66
2025-08-15FATE-0.31-7.848.61
2025-08-18FATE-0.31-17.138.48
2025-08-19FATE-0.40-17.138.48
2025-08-20FATE-0.40-17.138.48
2025-08-21FATE-0.40-17.138.48
2025-08-22FATE-0.40-17.138.48
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.29

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

-0.4

Institutional Transactions

-17.13

Beta

2.22

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

14

Growth Score

24

Sentiment Score

77

Actual DrawDown %

99.1

Max Drawdown 5-Year %

-99.4

Target Price

4.95

P/E

Forward P/E

PEG

P/S

15.66

P/B

0.5

P/Free Cash Flow

EPS

-1.45

Average EPS Est. Cur. Y​

-1.11

EPS Next Y. (Est.)

-1.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2025.05

Relative Volume

1.09

Return on Equity vs Sector %

-90.3

Return on Equity vs Industry %

-77.4

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

Fate Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading